GlassScriptPhysician profile
James P Miller
NPI 1598752560
$7,950.54
in general payments reported to CMS, 2019-2025
36 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,218 · 2020: $1,035 · 2021: $1,425 · 2022: $1,184 · 2023: $1,462 · 2024: $1,498 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,089.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,182.61 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $976.32 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $892.53 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $886.65 | 2019-2024 | Mounjaro, Jardiance, Trulicity |
| Glaxosmithkline, LLC. | $556.47 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $511.48 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $442.24 | 2019-2023 | |
| Pfizer INC. | $319.47 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $311.97 | 2019-2022 | |
| Abbott Laboratories | $290.56 | 2019-2024 | Freestyle Libre 3 |
| Amgen INC. | $260.84 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $244.68 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $173.71 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Abbvie INC. | $129.53 | 2021-2023 | |
| Esperion Therapeutics, INC. | $117.91 | 2021-2023 | Nexletol |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $90.12 | 2022-2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $64.32 | 2019-2025 | |
| Allergan, INC. | $54.39 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $48.48 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $46.46 | 2021 | |
| Amarin Pharma, INC. | $44.64 | 2019 | |
| Xeris Pharmaceuticals, INC. | $41.76 | 2022-2024 | Gvoke Hypopen |
| Vivus LLC | $33.42 | 2019 | |
| Dexcom, INC. | $27.59 | 2021-2023 | Dexcom G6 Transmitter |
| Zyla Life Sciences, INC. | $26.47 | 2019 | |
| Braemar Manufacturing, LLC | $20.84 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.92 | 2022 | |
| Intuitive Surgical, INC. | $18.96 | 2024 | |
| Preventice Services, LLC | $17.78 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.21 | 2023 | Camzyos |
| Alexion Pharmaceuticals, INC. | $16.20 | 2019 | |
| Rti Surgical, INC | $15.51 | 2023 | |
| Alvogen INC | $13.62 | 2022 | |
| Radius Health, INC. | $13.16 | 2019 | |
| Eisai INC. | $12.37 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.